JPWO2020065044A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020065044A5 JPWO2020065044A5 JP2021542268A JP2021542268A JPWO2020065044A5 JP WO2020065044 A5 JPWO2020065044 A5 JP WO2020065044A5 JP 2021542268 A JP2021542268 A JP 2021542268A JP 2021542268 A JP2021542268 A JP 2021542268A JP WO2020065044 A5 JPWO2020065044 A5 JP WO2020065044A5
- Authority
- JP
- Japan
- Prior art keywords
- trem
- vitro method
- strem
- measured
- human subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000338 in vitro Methods 0.000 claims 18
- 108010066451 Triggering Receptor Expressed on Myeloid Cells-1 Proteins 0.000 claims 16
- 102000018368 Triggering Receptor Expressed on Myeloid Cells-1 Human genes 0.000 claims 16
- 238000002560 therapeutic procedure Methods 0.000 claims 8
- 200000000018 inflammatory disease Diseases 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 206010040070 Septic shock Diseases 0.000 claims 4
- 230000036303 septic shock Effects 0.000 claims 4
- 206010051379 Systemic inflammatory response syndrome Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 208000001953 Hypotension Diseases 0.000 claims 2
- 206010053159 Organ failure Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000001077 hypotensive Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000002441 reversible Effects 0.000 claims 2
- 229920002033 ribozyme Polymers 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 229920002395 Aptamer Polymers 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229920000272 Oligonucleotide Polymers 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 108020004459 Small Interfering RNA Proteins 0.000 claims 1
- 229920001891 Small hairpin RNA Polymers 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 238000003271 compound fluorescence assay Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 230000000977 initiatory Effects 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- 230000000033 vasopressor Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024011668A JP2024056751A (ja) | 2018-09-28 | 2024-01-30 | 抗炎症療法に応答しやすい対象を特定するための可溶性ｔｒｅｍ－１レベルの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306277 | 2018-09-28 | ||
| EP18306277.7 | 2018-09-28 | ||
| PCT/EP2019/076263 WO2020065044A1 (fr) | 2018-09-28 | 2019-09-27 | Utilisation de niveaux de trem-1 solubles pour identifier des sujets susceptibles de répondre à une thérapie anti-inflammatoire |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024011668A Division JP2024056751A (ja) | 2018-09-28 | 2024-01-30 | 抗炎症療法に応答しやすい対象を特定するための可溶性ｔｒｅｍ－１レベルの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513324A JP2022513324A (ja) | 2022-02-07 |
| JPWO2020065044A5 true JPWO2020065044A5 (fr) | 2022-10-04 |
Family
ID=63798919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542268A Pending JP2022513324A (ja) | 2018-09-28 | 2019-09-27 | 抗炎症療法に応答しやすい対象を特定するための可溶性ｔｒｅｍ－１レベルの使用 |
| JP2024011668A Pending JP2024056751A (ja) | 2018-09-28 | 2024-01-30 | 抗炎症療法に応答しやすい対象を特定するための可溶性ｔｒｅｍ－１レベルの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024011668A Pending JP2024056751A (ja) | 2018-09-28 | 2024-01-30 | 抗炎症療法に応答しやすい対象を特定するための可溶性ｔｒｅｍ－１レベルの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210364532A1 (fr) |
| EP (1) | EP3856222A1 (fr) |
| JP (2) | JP2022513324A (fr) |
| KR (1) | KR20210109519A (fr) |
| CN (1) | CN113164546A (fr) |
| AU (1) | AU2019348534A1 (fr) |
| BR (1) | BR112021005808A2 (fr) |
| CA (1) | CA3114503A1 (fr) |
| IL (1) | IL281846A (fr) |
| MX (1) | MX2021003577A (fr) |
| WO (1) | WO2020065044A1 (fr) |
| ZA (1) | ZA202102071B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN116490199A (zh) * | 2020-06-05 | 2023-07-25 | 伊诺特伦公司 | 用于治疗患有冠状病毒感染的受试者的trem-1抑制剂 |
| EP4329809A2 (fr) * | 2021-04-30 | 2024-03-06 | The Children's Hospital Of Philadelphia | Compositions et méthodes de traitement de la septicémie chez des patients au moyen d'anticorps anti-light |
| CN113755580B (zh) * | 2021-09-13 | 2023-10-27 | 中国医学科学院阜外医院 | 一种治疗和/或缓解淋巴水肿的药物干预靶点及其应用 |
| WO2024005275A1 (fr) * | 2022-06-29 | 2024-01-04 | 서울대학교병원 | Procédé d'évaluation de la sensibilité aux antibiotiques dans le corps humain en utilisant le strem -1 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060084082A1 (en) | 1997-03-07 | 2006-04-20 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| GB0401730D0 (en) * | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
| AU2011237851B2 (en) * | 2010-04-08 | 2015-02-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Inhibiting peptides derived from TREM-Like Transcript 1 (TLT-1) and uses thereof |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| EP3196214B1 (fr) | 2012-02-15 | 2019-07-31 | Novo Nordisk A/S | Anticorps liant et bloquant un récepteur de déclenchement exprimé sur des cellules-1 myéloïdes (trem-1) |
-
2019
- 2019-09-27 BR BR112021005808-7A patent/BR112021005808A2/pt unknown
- 2019-09-27 AU AU2019348534A patent/AU2019348534A1/en active Pending
- 2019-09-27 WO PCT/EP2019/076263 patent/WO2020065044A1/fr unknown
- 2019-09-27 US US17/280,358 patent/US20210364532A1/en active Pending
- 2019-09-27 CN CN201980077175.3A patent/CN113164546A/zh active Pending
- 2019-09-27 MX MX2021003577A patent/MX2021003577A/es unknown
- 2019-09-27 KR KR1020217011870A patent/KR20210109519A/ko unknown
- 2019-09-27 CA CA3114503A patent/CA3114503A1/fr active Pending
- 2019-09-27 JP JP2021542268A patent/JP2022513324A/ja active Pending
- 2019-09-27 EP EP19783243.9A patent/EP3856222A1/fr active Pending
-
2021
- 2021-03-25 IL IL281846A patent/IL281846A/en unknown
- 2021-03-26 ZA ZA2021/02071A patent/ZA202102071B/en unknown
-
2024
- 2024-01-30 JP JP2024011668A patent/JP2024056751A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gutmann et al. | SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care | |
| Ma et al. | Single-cell transcriptomic atlas of primate cardiopulmonary aging | |
| Wang et al. | Targeting IL-17 attenuates hypoxia-induced pulmonary hypertension through downregulation of β-catenin | |
| EP3141904B1 (fr) | Procédés, dispositifs et kits de détection ou surveillance d'une lésion rénale aiguë | |
| Cao et al. | MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: an update | |
| Ouziel et al. | The ST2 pathway is involved in acute pancreatitis: a translational study in humans and mice | |
| US20160244764A1 (en) | Methods for predicting the progression and treating a chronic kidney disease in a patient | |
| JP5619016B2 (ja) | 重症敗血症及び敗血症性ショック中の死亡の危険性が高い患者を迅速に決定するための方法及びキット | |
| Singh et al. | HMGB1 facilitates hypoxia‐induced vWF upregulation through TLR2‐MYD88‐SP1 pathway | |
| JP2022513324A (ja) | 抗炎症療法に応答しやすい対象を特定するための可溶性ｔｒｅｍ－１レベルの使用 | |
| Nakamura et al. | Serum levels of interleukin‐18‐binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis | |
| Zhang et al. | Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling | |
| CN111655724A (zh) | Smc介导的疾病的治疗 | |
| WO2014139883A1 (fr) | Cibles et composés moléculaires, et méthodes utilisées pour les identifier, dans le cadre du traitement de la fibrose | |
| An et al. | Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor | |
| Tuttolomondo et al. | Effects of intravenous furosemide plus small‐volume hypertonic saline solutions on markers of heart failure | |
| JP2013527454A (ja) | 併用療法及び治療耐性評価方法 | |
| JPWO2020065044A5 (fr) | ||
| AU2012216816B2 (en) | Means and methods for diagnosing and/ or treating a subject at risk of developing heart failure | |
| Liu et al. | Rh family C glycoprotein contributes to psoriatic inflammation through regulating the dysdifferentiation and cytokine secretion of keratinocytes | |
| CA2908889C (fr) | Traitement de la resistance a l'insuline par des inhibiteurs du facteur de transcription tsc22d4 | |
| Yang et al. | Circular RNA circ_0001445 alleviates the ox-LDL-induced endothelial injury in human primary aortic endothelial cells through regulating ABCG1 via acting as a sponge of miR-208b-5p | |
| JP6698154B2 (ja) | 腎症診断用のマーカーとしてのｓｈ３ｙｌ１の用途 | |
| KR102599833B1 (ko) | SARS-CoV-2-유도성 패혈증의 진단 또는 예후 예측용 바이오마커 | |
| Hirabayashi et al. | Possible pro‐inflammatory role of heparin‐binding epidermal growth factor‐like growth factor in the active phase of systemic sclerosis |